Shares of Smith & Nephew plc (NYSE:SNN – Get Free Report) have earned an average recommendation of “Moderate Buy” from the six ratings firms that are currently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company.
Several equities research analysts recently issued reports on the company. Deutsche Bank Aktiengesellschaft started coverage on Smith & Nephew in a research note on Wednesday, July 24th. They set a “buy” rating for the company. StockNews.com raised Smith & Nephew from a “buy” rating to a “strong-buy” rating in a report on Monday, August 5th. Finally, UBS Group upgraded shares of Smith & Nephew from a “neutral” rating to a “buy” rating in a research report on Wednesday, June 5th.
Get Our Latest Stock Analysis on SNN
Smith & Nephew Price Performance
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of SNN. International Assets Investment Management LLC purchased a new stake in shares of Smith & Nephew in the 4th quarter worth about $716,000. abrdn plc bought a new stake in Smith & Nephew during the 4th quarter valued at approximately $4,957,000. Signaturefd LLC boosted its position in Smith & Nephew by 51.6% during the 4th quarter. Signaturefd LLC now owns 8,070 shares of the medical equipment provider’s stock valued at $220,000 after acquiring an additional 2,748 shares in the last quarter. CWM LLC grew its holdings in shares of Smith & Nephew by 68.6% during the 4th quarter. CWM LLC now owns 954 shares of the medical equipment provider’s stock worth $26,000 after acquiring an additional 388 shares during the period. Finally, GAMMA Investing LLC bought a new position in shares of Smith & Nephew in the 4th quarter worth approximately $53,000. Institutional investors own 25.64% of the company’s stock.
Smith & Nephew Company Profile
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.
Recommended Stories
- Five stocks we like better than Smith & Nephew
- P/E Ratio Calculation: How to Assess Stocks
- CAVA Stock Rallies as Earnings Confirm It’s a Top Growth Play
- Using the MarketBeat Stock Split Calculator
- 3 High Short-Interest Stocks Poised for a Rate Cut Squeeze
- What is Short Interest? How to Use It
- MarketBeat Week in Review – 8/19 – 8/23
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.